Listed by the National Monitoring Board | All pharmaceutical people noticed

According to the CCTV news report, on March 23rd, the People's Republic of China State Supervision Commission unveiled in Beijing, held a new deputy director of the National Supervision Commission, and members of the constitutional oath ceremony.

On March 11, the 13th session of the National People's Congress reviewed and passed the constitutional amendment, and the Supervisory Committee was formally incorporated into the Constitution. The Ministry of Supervision merged with the newly formed National Supervision Commission, and no longer maintained the Ministry of Supervision, the National Bureau of Corruption Prevention.

The supervisory committee is the national anti-corruption agency, which is in parallel with the 'two houses of the government' (the State Council, the Supreme People's Court, and the Supreme People's Procuratorate).

On March 20th, the "Third National People's Congress" voted and passed the "People's Republic of China Supervision Law."

The institutional reform of the State Council gave a great significance to the constitutional status of the Supervisory Committee. The results of reforms have been increased to the constitutional provisions. This provides the constitutional basis for the establishment of the supervision law and the establishment of national and local supervisory committees at all levels.

In addition, when the Premier of the State Council made a report on the work of the government in 2018, he repeatedly mentioned the word “anti-corruption”, which shows that for anti-corruption work, it is absolutely the most important task for 2018 work.

In fact, from the moment the horn blew, the fight against medical corruption without gunpowder could no longer stop.

As early as October 28, 2009, the Supervision Department of the Central Commission for Discipline Inspection opened a nationwide disciplinary inspection and reporting website. The report website accepted complaints against party members, party organizations, and administrative inspectors who violated Party and government disciplinary activities, as well as the construction of the party's integrity and clean government, and anti-corruption. Work suggestions.

Among the five aspects that the Central Discipline-Inspecting Party encourages to report, it includes the violation of the responsibility system for building a clean and honest government. The details are as follows:

Party committees at or above the county level perform their main responsibilities, and the disciplinary committee fails to perform its supervisory responsibilities, resulting in corruption, collusion, or serious corruption cases occurring in the system in its own department in the region; In the eight stipulated spirits, there was a serious 'four winds' problem and the leadership was held responsible. We all know that in recent years, there have been many corruption cases in the medical industry and the string case has been investigated.

In November 2017, the former Party Secretary of Wannan Medical College, Huang (at the office level), was arrested for investigation of bribery crimes, which led to medical corruption cases;

In 2017, Hefei Health System broke out, health system officials, hospital Dean, doctors and other 30 people were arrested and investigated.

In April 2017, a corruption case broke out in two air hospitals in Jiangsu: Four people from the De'an Hospital in Changzhou were investigated for bribery; the five department heads of the People's Hospital of Jiangyin City, Wuxi, and the laboratory of the hospital were both sued for bribery.

In February 2015, after the National Health and Family Planning Commission issued the “Large-scale Hospital Inspection Program (2015-2017)”, the provincial health and planning commissions successively launched a plan to inspect large-scale large hospitals. The focus of hospital inspections is anti-corruption.

In July 2015, the National Health and Development Commission, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Finance, the Ministry of Human Resources and Social Security, the Ministry of Commerce, the State Administration of Taxation, the State Administration for Industry and Commerce, and the Food and Drug Administration and other 9 ministries jointly issued the “Correction of Pharmaceutical Purchases and Marketing and Medical Services in 2015”. "The main points of governance in the special issues", many ministries work together to carry out anti-corruption medical treatment, in-depth management of commercial drug buying and selling areas of commercial bribery.

At the end of 2016, after CCTV exposed the 'return door', various special anti-corruption campaigns were launched around the country. At that time, informed sources stated that 9 ministries and commissions would work together drug The Ministry of Public Security will also participate in the rectification operations in the field of purchase and sale. The main targets of inspection are hospitals, pharmaceutical companies and medicine representative.

In February 2017, the National Health and Family Planning Commission and the State Administration of Traditional Chinese Medicine jointly issued the Opinions on Strengthening the Construction of Health and Family Planning System, and proposed to formulate information sharing and joint punishment implementation measures for the health and family planning system. After the judiciary’s judgment or arbitration agency ruled, the institutions and individuals that had occurred in the fields of pharmaceutical purchase and sale and medical service malpractice were included in the health and family planning system credit reporting system, and announced to the public, implementing the industry banned entry system.

According to this document, inspections of large-scale hospitals across the country continue to expand coverage and depth. In 2018, all tertiary medical institutions carried out hospital inspections. By 2020, more than Grade 2 medical institutions will carry out hospital inspections.

We can see that although the years from 2015 to 2017 have passed, anti-corruption continues, and from 2018 to 2020, it will be a new anti-corruption high-pressure year.

The two sessions have already closed, which has brought about major changes in the pharmaceutical market. The Food and Drug Administration has withdrawn, the Medical Reform Office has gone, the Health and Family Planning Commission has changed its name, the National Medical Insurance Bureau was established, the inspection committee came, and the policy became a big hit. The environment changes.

For pharmaceutical companies, following the policy, adapting to changes in various institutions is the focus of attention.

The National Monitoring and Supervision Commission was established, and its monitoring targets include managers of publicly-owned medical institutions. According to Xinhuanet’s report, currently the Central Procuratorate’s anti-corruption, anti-corruption and prevention departmental functions, agencies and agencies The name of the prosecutor police officer has completed the transfer on time.

As early as December 27, 2013, the National Health and Family Planning Commission issued the "Regulations on Establishing Bad Records of Commercial Bribery in the Field of Pharmaceutical Purchases and Marketing", which clearly stipulates:

Persons in charge of medical institutions, drug purchasers, doctors, and other related personnel receive pharmaceutical production and management companies and proxy Where a person grants property or other benefits, he shall be disciplined and confiscation shall be confiscated of illegal gains; if the practitioner has a serious violation of the law, the health and family planning administrative department shall revoke its practice certificate; if it constitutes a crime, criminal responsibility shall be investigated according to law.

The pharmaceutical production operation that was once included in the bad record of local commercial bribery enterprise And its agents, public medical institutions within the province-level region or medical and health institutions that receive financial funds are not allowed to purchase their medicines, medical equipment and medical consumables, or other public medical institutions within provincial areas within two years after the publication of the bad record list. 2. The medical and health institutions that receive financial funds are bidding within two years, and the company's products are treated as points when purchasing scores.

For the second time or more that is included in the bad record of commercial bribery within five years, all public medical institutions in the country or medical and health institutions that receive financial funds must not purchase their medicines, medical equipment and medical consumables within two years.

The health and family planning administrative department should establish a communication mechanism with the judicial organs and relevant departments of supervision, finance, commerce, industry and commerce, and food and drug supervision, and inform each other of commercial bribery cases and investigation results in the field of pharmaceutical purchases and sales.

On December 22, 2017, the “Administrative Measures for the Registration and Filing of Medical Representatives (Trial) (Draft for Comment)” issued by the State Food and Drug Administration and the National Health and Family Planning Commission clearly stated that pharmaceutical representatives must not assume drug sales tasks and must not participate in statistics. The amount of drug prescriptions prescribed by doctors must not directly sell physical drugs, collect money, deal with purchase and sales bills, and must not conduct commercial bribery, and must not directly provide donations to department or individual of medical and health institutions; it must not mislead doctors to use drugs. Exaggerate or mislead curative effects, not hide adverse drug reactions.

From this it can be seen that the National Monitoring and Supervision Commission has also become a department that pharmaceutical companies must pay attention to. The anti-corruption policy will make the market investment of pharmaceutical companies more and more transparent, and the composition of market expenses can be traced back to actual behavior, making it increasingly difficult to make counterfeiting. If you want to continue to use the sales model with gold, the cost of counterfeiting will become higher and higher.

With sales of gold, the company pays a corresponding amount of rewards based on the number of prescriptions prescribed by the doctor. With the combination of the SFDA and the Medical Insurance Board, for pharmaceutical companies, the sales model with gold will also need to be completely adjusted to adapt to the situation. Changes and policy requirements.

In addition, after the implementation of the filing system, the two-vote system, zero markup, pharmacy custody, and secondary bargaining, the adjustment of the marketing model will be a great challenge for many pharmaceutical companies.